A2M Gene

A2M Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">a2m</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>A2M</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Alpha-2-macroglobulin</td>
</tr>
<tr>
<td class="label">Synonyms</td>
<td>A2MP, alpha-2-M, α2M</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>12p13.31 (human)</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>2</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P01023</td>
</tr>
<tr>
<td class="label">Gene Family</td>
<td>α2-macroglobulin family</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>1450 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~720 kDa (tetramer)</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Development Stage</td>
</tr>
<tr>
<td class="label">A2M enhancement</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">A2M mimetics</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Protease-A2M modulators</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/ami" style="color:#ef9a9a">AMI</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" st

A2M Gene

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">a2m</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>A2M</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Alpha-2-macroglobulin</td>
</tr>
<tr>
<td class="label">Synonyms</td>
<td>A2MP, alpha-2-M, α2M</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>12p13.31 (human)</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>2</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P01023</td>
</tr>
<tr>
<td class="label">Gene Family</td>
<td>α2-macroglobulin family</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>1450 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~720 kDa (tetramer)</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Development Stage</td>
</tr>
<tr>
<td class="label">A2M enhancement</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">A2M mimetics</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>Preclinical</td>
</tr>
<tr>
<td class="label">Protease-A2M modulators</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/ad" style="color:#ef9a9a">AD</a>, <a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/ami" style="color:#ef9a9a">AMI</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">83 edges</a></td>
</tr>
</table>

Overview

A2M (Alpha-2-Macroglobulin) encodes a large plasma glycoprotein that functions as a broad-spectrum proteinase inhibitor and molecular chaperone. A2M has been extensively studied in the context of neurodegenerative diseases, particularly Alzheimer's disease, where genetic variants have been associated with disease risk. This protein plays critical roles in protein homeostasis, immune modulation, and neuroprotection, making it a compelling therapeutic target.

Gene Information

Normal Function

Protein Structure

A2M is a homotetrameric protein, each subunit approximately 180 kDa. The protein possesses a unique "trap" mechanism:

Structural features:

• Bait region: Central domain containing protease cleavage sites
• Thiol ester bonds: Internal reactive esters for covalent binding
• Native conformation: Large "sponge-like" structure
• Cleaved form: Conformationally altered after protease binding

Functions

A2M serves multiple biological roles:

Tissue Expression

A2M is expressed in:

• Liver: Primary source of systemic A2M
• Astrocytes: Major cellular source in the brain
• Adipose tissue: Local production
• Lung: Minor expression

Role in Neurodegeneration

Alzheimer's Disease

A2M has been extensively studied in AD pathogenesis:

Genetic association:

• GWAS have identified A2M polymorphisms associated with AD risk
• The A2M deletion polymorphism (A2M-2) linked to increased risk
• Earlier age of disease onset in carriers
• Accelerated cognitive decline

Parkinson's Disease

A2M has emerging relevance to PD:

• Alpha-synuclein binding: A2M can bind α-synuclein aggregates
• Neuroinflammation: Modulates microglial activation
• Protein clearance: Enhanced clearance of misfolded proteins
• Clinical associations: Altered A2M levels in PD patients

Other Neurodegenerative Conditions

Amyotrophic lateral sclerosis (ALS):

• Altered A2M levels in some ALS patients
• Potential for monitoring disease progression

• A2M may help clear mutant huntingtin protein
• Altered expression in disease models

Molecular Mechanisms

Aβ Binding and Clearance

A2M interacts with Aβ through multiple mechanisms:

Binding interactions:

• Thiol ester-mediated covalent binding
• Surface adsorption to A2M structure
• Complex formation with proteases

• Receptor-mediated endocytosis (LRP1)
• Degradation in lysosomes
• Export across blood-brain barrier

Chaperone Activity

A2M's chaperone function is crucial:

• Protein aggregation prevention: Binds unfolded proteins
• Proteostasis maintenance: Supports protein quality control
• Stress response: Upregulated under cellular stress

Immune Modulation

A2M modulates neuroinflammation:

• Cytokine binding: Sequesters pro-inflammatory cytokines
• Phagocytosis enhancement: Promotes microglial clearance
• Complement regulation: Interacts with complement system

Signaling Pathways

LRP1-Mediated Signaling

A2M signals through LRP1 (LDL receptor-related protein 1):

A2M → LRP1 → Src family kinases
↓
MAPK activation
↓
Gene transcription
↓
Cell survival/neuroprotection

A2M-Protease Complexes

Protease-A2M complexes signal differently:

• LRP1 recognition: Rapid clearance
• Cytokine release: May promote inflammation
• Tissue remodeling: Matrix metalloproteinase regulation

Therapeutic Implications

Therapeutic Strategies

Clinical Status

• No A2M-targeted therapies in clinical trials for neurodegeneration
• Research ongoing in preclinical models
• Biomarker potential for disease monitoring

Patient Selection

Potential biomarkers:

• A2M levels: Blood and CSF measurements
• Genetic variants: A2M genotyping
• Protease-A2M complexes: Disease activity markers

Research Tools and Methods

Molecular Tools

• CRISPR-Cas9: A2M knockout and knock-in models
• Recombinant A2M: Protein production and characterization
• Antibodies: Detection and functional studies
• Fluorescent reporters: Expression tracking

Animal Models

• A2M knockout mice: Accelerates pathology in AD models
• Transgenic models: A2M overexpression
• AD model crosses: 5×FAD × A2M-/-, APP/PS1 × A2M-/-

Experimental Approaches

• ELISA: A2M level measurements
• Western blotting: Protein analysis
• Immunohistochemistry: Brain localization
• Behavioral testing: Cognitive and motor assessments

Comparative Biology

Species Conservation

A2M shows complex evolution:

• Mammals: High conservation, functional orthologs
• Birds: Present but diverged function
• Fish: Primitive forms
• Evolution: Expanded immune functions in mammals

Ortholog Relationships

• Human A2M most studied
• Mouse and rat models widely used
• Primate models for translational studies

Clinical Translation

Diagnostic Applications

Biomarkers:

• Plasma A2M levels: Elevated in AD
• CSF A2M: Correlates with disease severity
• A2M/Aβ complexes: Diagnostic potential

• Progression markers
• Treatment response indicators
• Prognostic value

Therapeutic Development

Approaches in development:

• Recombinant A2M protein therapy
• Gene therapy for A2M expression
• Small molecule A2M enhancers
• Cell-based approaches

Animal Models

Knockout Studies

A2M knockout mice show:

• Accelerated Aβ accumulation
• Impaired memory function
• Enhanced neuroinflammation
• Exacerbated tau pathology

Overexpression Studies

A2M transgenic mice demonstrate:

• Reduced Aβ pathology
• Improved cognitive function
• Modest neuroinflammation
• Protective phenotype

Structural Biology

Protein Domains

A2M contains multiple functional domains:

Bait region:

• Protease cleavage sites
• Susceptible to multiple proteases
• Triggers conformational change

• Reactive internal esters
• Covalent binding capacity
• Forms stable complexes

• Receptor binding sites
• Clearance signal
• Structural stability

Conformational Changes

Native state:

• Extended "S" shape
• Bait region accessible
• Thiol esters protected

• "Clamped" conformation
• Protease trapped inside
• Thiol esters exposed

Future Directions

Research Priorities

Unmet Needs

See Also

• [Alpha-2-Macroglobulin Protein](/proteins/alpha-2-macroglobulin)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Protein Homeostasis](/mechanisms/protein-homeostasis)
• [Neuroinflammation](/mechanisms/neuroinflammation)

External Links

• [NCBI Gene: A2M](https://www.ncbi.nlm.nih.gov/gene/2)
• [GeneCards: A2M](https://www.genecards.org/cgi-bin/carddisp.pl?gene=A2M)
• [UniProt: A2M](https://www.uniprot.org/uniprot/P01023)
• [OMIM: A2M](https://omim.org/entry/104150)
• [Ensembl: A2M](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108349)

Brain Atlas Resources

• [Allen Human Brain Atlas](https://human.brain-map.org/) — gene expression data
• [BrainSpan Atlas](https://brainspan.org/) — developmental transcriptome
• [Allen Mouse Brain Atlas](https://mouse.brain-map.org/) — mouse brain gene expression

References

Pathophysiology

Role in Protein Aggregation

A2M plays a critical role in preventing protein aggregation:

Chaperone mechanism:

• Binds to hydrophobic regions of misfolded proteins
• Prevents nucleation and growth of aggregates
• Facilitates refolding or clearance
• Acts as a "molecular sponge" for toxic species

• Recognizes various aggregate types
• Facilitates phagocytic clearance
• Enhances proteasome-mediated degradation
• Supports autophagy pathways

Neuroinflammation Modulation

A2M modulates inflammatory responses:

Pro-inflammatory effects:

• A2M-protease complexes can activate cells
• Cytokine release upon complex formation
• Complement system interactions

• Sequestration of active proteases
• Cytokine binding and neutralization
• Promotion of tissue repair

Blood-Brain Barrier Interactions

A2M crosses the BBB via receptor-mediated transport:

Bidirectional transport:

• LRP1-mediated efflux from brain
• Receptor-mediated influx from plasma
• Regulated by A2M conformation

• Peripheral A2M can enter CNS
• Therapeutic delivery possibilities
• Biomarker interpretation considerations

Genetic Studies

GWAS Findings

A2M polymorphisms have been consistently associated with AD:

Risk variants:

• rs3833628 (A2M deletion): Increased risk
• rs429533 (intronic): Modest effect
• Multiple rare variants identified

• Some coding variants show protection
• Functional studies ongoing

Expression Studies

A2M expression changes in disease:

AD brain:

• Elevated A2M in hippocampus
• Astrocytic upregulation
• Correlation with pathology

• Variable changes reported
• Associated with disease progression

Therapeutic Approaches

Protein-Based Therapy

Recombinant A2M approaches:

• Purified A2M administration
• Modified A2M variants
• A2M fragment therapeutics

Gene Therapy

Viral vector delivery:

• AAV-mediated brain expression
• Liver-targeted for systemic effects
• Regulated expression systems

Small Molecule Modulators

Drug discovery efforts:

• A2M expression enhancers
• Protease-A2M complex inhibitors
• Receptor signaling modulators

Combination Strategies

Rational combinations:

• A2M + Aβ immunotherapy
• A2M + tau-targeted approaches
• A2M + neuroprotective agents

Biomarkers and Diagnostics

A2M as Biomarker

Blood markers:

• Total A2M levels: Elevated in AD
• A2M/Aβ complexes: Diagnostic potential
• Protease-A2M ratios: Disease activity

• A2M concentration: Correlates with severity
• Phosphorylated A2M: Emerging marker
• Complexes with proteases

Clinical Utility

• Disease diagnosis support
• Progression monitoring
• Treatment response assessment
• Prognostic information

Epigenetic Regulation

Transcriptional Control

A2M expression is regulated:

Promoter elements:

• Glucocorticoid response elements
• Cytokine-responsive elements
• Developmental regulators

• STAT3: IL-6 mediated induction
• NF-κB: Inflammatory regulation
• C/EBPβ: Acute phase response

DNA Methylation

Epigenetic modifications:

• Promoter methylation patterns
• Disease-associated changes
• Environmental influences

Pathway Diagram

Key molecular relationships involving a2m from the SciDEX knowledge graph:

Pathway Diagram

The following diagram shows the key molecular relationships involving A2M Gene discovered through SciDEX knowledge graph analysis: